CCM® Therapy — My Approach to Identifying Patients

CCM® Therapy

M. Emig, S. Toth-Manikowski, D. McCaskill

Rivaroxaban's Role in PAD Management: Where Do We Stand?

UPMC

J. Hornick

HRS 2024: Cardiac Contractility Modulation - Don’t Wait!

CCM® Therapy

R. Kahwash

Five Things Every Internist Should Know About Anticoagulants

McMaster University Department of Medicine

S. Mithoowani

Perioperative Management of Anticoagulants: Podiatry Education Series

Michigan Medicine - Podiatry

M. Munson

Medical Management of Peripheral Arterial Disease

NY Endovascular Summit

H. Kamran

Heart Failure with Preserved Ejection Fraction: Current Perspectives…

American College of Cardiology

S. Shah

Challenges and Opportunities with Contemporary GDMT (Dr. Heywood)

CVRx | Barostim

J. Thomas Heywood

ESC 2023: Baroreflex Activation Therapy for HFrEF Patients: Long-Ter…

CVRx | Barostim

W. Abraham, F. Arribas, M. Zile

Challenges and Opportunities with Contemporary GDMT

CVRx | Barostim

D. Yaranov

ESC 2023: Unmet needs and opportunities with device therapies of HFr…

CVRx | Barostim

W. Abraham

Baroreflex Activation Therapy Overview of Clinical Data

CVRx | Barostim

L. Tsao

How to Detect and Treat Heart Failure with Preserved Ejection Fracti…

Houston Methodist DeBakey Heart and Vascular Center

Extended Anticoagulation for VTE

Jeffrey Weitz

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …

American Heart & Vascular Institute

M. Kittleson

ISCHEMIA Trial: Are We Overusing Cardiac Stents? Is Revascularizatio…

American Heart & Vascular Institute

B. Reddy

Diabetes and Heart Failure: The New Frontier

Mount Sinai Advanced Innovations in Heart Failure Symposium 2019

E. Braunwald

The CCM Solution: How Does it Work and What Does it Do?

CCM® Therapy

N. Varma

The ISCHEMIA Trial: Are There Differences in Primary and Secondary O…

Mount Sinai

G. Stone

Barostim Clinical Evidence

CVRx | Barostim

L. Grazette